- UAE-based Mindshift Capital has invested in the Series C raise of US-based OtoNexus Medical Technologies
- This marks the eight investment for Mindshift’s inaugural fund which invests in women-led startups around the world. The VC has so far invested across the US, Middle East and Asia
- OtoNexus has developed the world’s first ultrasound hand-held device to evaluate ear infections and increase diagnostic accuracy
Mindshift Capital has invested in the Series C raise of US-based OtoNexus Medical Technologies, recognised as one of the leading US companies at the forefront of infection control solutions.
Led by CEO Caitlin Cameron, OtoNexus has developed the world's first ultrasound hand-held device to evaluate middle ear infection and increase diagnostic accuracy. Middle ear infections are the #1 reason for antibiotic prescriptions and the #1 reason for surgery in children. However, current detection accuracy is only around 50% in the key differentiation of viral versus bacterial infections. This new device improves accuracy and efficiency of diagnosis with results within 2 seconds.
“This is an exciting investment for Mindshift Capital,” said Founding Partner, Heather Henyon - “Mindshift Capital invests in exceptional female founded companies at the forefront of innovation in sectors such as medtech. OtoNexus Medical Technologies is solving one of the biggest issues of our time – the overuse of antibiotics.
The pedigree of the founding team and momentum within the business is exceptional and we are proud to join OtoNexus’ investors. We are delighted to welcome Caitlin Cameron and team into the Mindshift portfolio. We can see excellent international expansion opportunities and are looking forward to future success.
In addition, this investment is evidence of the high quality of deal flow that we are experiencing as a result of our investment focus across core sectors with female founders and Mindshift’s global networks.”
This the eighth investment for Mindshift Capital in its inaugural fund. To date the fund spans the US, Middle East and Asia. The addition of OtoNexus demonstrates further growth for the fund in securing investments in global companies, and showcasing the collaborative and agile reach of the Mindshift team amongst strong co-investors.
Caitlin Cameron, CEO OtoNexus Medical Technologies says; “We are targeting a 50% reduction in the use of antibiotics for middle ear infections. This is a global problem and the investment from Mindshift Capital is recognition of the value of our unique technology ,to empower the physician’s fight against overuse of antibiotics and improve the treatment of middle ear infections. Further global reach means that more healthcare practitioners and therefore families will benefit from our work.
The Mindshift team show us how global collaborations from a gender-lens fund make a difference where it matters, in better healthcare for all. Working alongside a fellow female founded team cements our shared commitment to bringing innovative technology to a world stage”